(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.27%) $78.32
(0.33%) $2.15
(0.49%) $2 319.80
(1.75%) $27.16
(-0.39%) $961.55
(0.01%) $0.929
(-0.09%) $10.86
(-0.02%) $0.797
(0.00%) $91.45
0.00% £ 164.80
Live Chart Being Loaded With Signals
Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees...
Stats | |
---|---|
Tagesvolumen | 203 762 |
Durchschnittsvolumen | 8.30M |
Marktkapitalisierung | 0.00 |
EPS | £-0.00834 ( 2019-06-29 ) |
Last Dividend | £19.00 ( 2021-06-01 ) |
Next Dividend | £0 ( N/A ) |
P/E | 0.0800 |
ATR14 | £0 (0.00%) |
Vectura Group PLC Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Vectura Group PLC Finanzdaten
Annual | 2020 |
Umsatz: | £190.60M |
Bruttogewinn: | £101.40M (53.20 %) |
EPS: | £0.188 |
FY | 2020 |
Umsatz: | £190.60M |
Bruttogewinn: | £101.40M (53.20 %) |
EPS: | £0.188 |
FY | 2019 |
Umsatz: | £178.30M |
Bruttogewinn: | £95.30M (53.45 %) |
EPS: | £-0.0340 |
FY | 2018 |
Umsatz: | £160.50M |
Bruttogewinn: | £98.90M (61.62 %) |
EPS: | £-0.143 |
Financial Reports:
No articles found.
Vectura Group PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £6.50 | 2019-10-14 |
Last Dividend | £19.00 | 2021-06-01 |
Next Dividend | £0 | N/A |
Payout Date | 2021-06-11 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £25.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.69 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.35 | |
Div. Directional Score | 8.24 | -- |
Year | Amount | Yield |
---|---|---|
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TYMN.L | Dividend Knight | 2023-08-03 | Annually | 29 | 2.69% | |
MGCI.L | Dividend King | 2023-08-03 | Quarterly | 6 | 3.54% | |
CTEC.L | Dividend Knight | 2023-08-17 | Semi-Annually | 8 | 1.46% | |
SCP.L | Dividend Knight | 2023-07-13 | Semi-Annually | 31 | 1.83% | |
HTG.L | Dividend King | 2023-10-05 | Semi-Annually | 32 | 1.82% | |
BCPT.L | Dividend King | 2023-09-14 | Monthly | 20 | 2.80% | |
WKP.L | Dividend Junior | 2023-07-06 | Annually | 31 | 2.53% | |
NAIT.L | Dividend Knight | 2023-07-20 | Quarterly | 53 | 2.33% | |
ECK.L | Dividend Knight | 2023-09-21 | Annually | 14 | 0.93% | |
SOM.L | Dividend King | 2023-09-21 | Semi-Annually | 18 | 5.37% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.642 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.184 | 1.200 | 3.87 | 4.65 | [0 - 0.3] |
returnOnEquityTTM | 0.254 | 1.500 | 8.29 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 0.923 | 0.800 | 9.28 | 7.42 | [0.8 - 2.5] |
cashRatioTTM | 0.923 | 1.500 | 5.99 | 8.98 | [0.2 - 2] |
debtRatioTTM | 0.00631 | -1.500 | 9.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 1 314.00 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0380 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0181 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00771 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.532 | 1.000 | 4.47 | 4.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.689 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.90 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.286 | 0.800 | -1.425 | -1.140 | [0.5 - 2] |
Total Score | 12.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.78 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.254 | 2.50 | 8.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0181 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0380 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.130 | 1.000 | 9.25 | 0 | [0.1 - 0.5] |
Total Score | 4.35 |
Vectura Group PLC
Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees. The firm's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.